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THE AUTHORS REPLY
We appreciate the points made by Lifson et al. (1) regard-
ing our study (2). We agree that standard deﬁnitions, multiple
reviewer adjudication, and clinical judgement on the part of
reviewers are all necessary for myocardial infarction (MI)
adjudication. These were key strengths of our study. We also
wholeheartedly agree with Lifson et al. on the importance
of reviewing the primary data and not just case report forms.
In fact, we avoid case report forms entirely, and reviews are
entirely based on primary data.
We agree with Lifson et al. regarding the beneﬁts of being
able to categorize events based on degree of diagnostic cer-
tainty: We used the categories of deﬁnite and probable. We
would further highlight the importance of distinguishing pri-
mary spontaneous MI events from events that occur second-
arily to other clinical syndromes, such as sepsis causing severe
hypotension. Secondary MIs are categorized as type 2 MIs
according to the universal MI deﬁnition (3). They have treat-
ment implications distinct from those of primary MIs, and we
have found them to be very common in persons with human
immunodeﬁciency virus (approximately half of all events).
We thank Lifson et al. for sharing their “INSIGHTs”
with us.
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RE: “ESTIMATED RATE OF REACTIVATION OF LATENT TUBERCULOSIS INFECTION IN THE UNITED STATES,
OVERALL AND BY POPULATION SUBGROUP”
Tuberculosis (TB) disease can occur soon after new infec-
tion (or reinfection) or many years thereafter through reacti-
vation of latent infection (1). Reliable estimates of rates of
reactivation are needed to predict the impact of interventions,
particularly in low-burden, high-income settings where there
may be little ongoing transmission.
Wewelcome Shea et al.’s (2) recent attempt to directly cal-
culate this rate for the whole of the United States using em-
pirical data. This could have permitted validation of currently
used estimates, obtained from mathematical models that ﬁt
to country-level historical data (3). Shea et al. reported differ-
ential TB reactivation rates by place of birth and human
immunodeﬁciency virus (HIV) status. If valid, these estimates
would also be valuable. However, we have concerns about the
assumptions used to derive these metrics from the limited data
available. To calculate the rate of TB reactivation in the United
States, Shea et al. divided estimates of the number of cases that
they attributed to reactivation by estimates of the number of
persons considered at risk of reactivation (2).
For the numerator (cases of reactivation TB), they used TB
isolates from 2006–2008 with a unique genotype within the
national genotyping database. Here, there were substantial
missing data, that is, TB cases without a genotype. Only
57% of all TB cases (73% of culture-positive cases) reported
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to the Centers for Disease Control and Prevention were geno-
typed. Results from modeling studies (4, 5) have shown that
the chance that cases will be incorrectly attributed to reactiva-
tion is increased if only a proportion of all cases are geno-
typed. This is a particular problem when cluster sizes are
small—which is likely here, given the low-burden setting.
The relatively short sampling framewould also result in over-
estimation of the number of cases due to reactivation (4, 5), as
might the authors’ assumption that transmission cannot occur
between persons living more than 50 km apart. Based on
ﬁndings by Glynn et al. (5), the missing data might result
in the proportion of cases attributable to reactivation being
overestimated by as much as 60%. The use of a relatively
nondiscriminatory typing method (12-locus MIRU-VNTR
[mycobacterial interspersed repetitive units–variable number
of tandem repeats] (6)) may have resulted in some bias in the
other direction but adds further uncertainty to these estimates.
The authors applied the proportion reactivated, calculated
from the observed data, to persons with missing genotypes,
thus amplifying any misclassiﬁcation.
For the denominator, Shea et al. estimated the prevalence
of latent infection from 7,386 persons who received a tuber-
culin skin test (TST) in cross-sectional health surveys in 1999
and 2000, and then extrapolated to estimate the prevalence of
latent infection for the entire US population (over 300 million
people) (2). While a 10-mm TST cutoff for all populations is
convenient, it feels simplistic given the known variation in
nontuberculous mycobacteria exposure both between countries
and within the United States (7) and the likely high coverage
of Bacillus Calmette-Guérin vaccination in the foreign-born
population.
The authors also present reactivation rates by HIV status,
under the assumption that the prevalence of latent infection
does not differ by HIV status (2). This is inappropriate,
given the fact that in high-income countries, these infections
are often co-located in disadvantaged communities (8).
When presenting estimates of reactivation rates among
HIV-negative persons, the authors might have attempted to
quantify the impact of their assumptions with sensitivity
analyses. These could have included allowing the TST cut-
point to vary (e.g., by place of birth) and adjusting the esti-
mated number of reactivation cases to account for potential
sampling bias. With regard to HIV, we agree with the authors
that better understanding of the interaction between HIV in-
fection and TB reactivation is needed, but the available data
do not allow valid calculation of these rates.
In summary, the questions addressed by Shea et al. (2)
are important, but the conclusions drawn should be more
cautious.
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Editor’s note: In accordance with Journal policy, Shea
et al. were asked whether they wished to respond to this
letter, but they chose not to do so.
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